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Abstract 
Tumor-associated macrophages (TAMs) enhance tumor growth in mice and are correlated with a worse 
prognosis for breast cancer patients. While early therapies sought to deplete all macrophages, current 
therapeutics aim to reprogram pro-tumor macrophages (M2) and preserve those necessary for 
anti-tumor immune responses (M1). Recent studies have shown that c-MYC (MYC) is induced in M2 
macrophages in vitro and in vivo where it regulates the expression of tumor-promoting genes. In a myeloid 
lineage MYC KO mouse model, MYC had important roles in macrophage maturation and function leading 
to reduced tumor growth. We therefore hypothesized that targeted delivery of a MYC inhibitor to 
established M2 TAMs could reduce polarization toward an M2 phenotype in breast cancer models. 
Methods: In this study, we developed a MYC inhibitor prodrug (MI3-PD) for encapsulation within 
perfluorocarbon nanoparticles, which can deliver drugs directly to the cytosol of the target cell through 
a phagocytosis independent mechanism. We have previously shown that M2-like TAMs express 
significant levels of the vitronectin receptor, integrin β3, and in vivo targeting and therapeutic potential 
was evaluated using αvβ3 integrin targeted rhodamine-labeled nanoparticles (NP) or integrin 
αvβ3-MI3-PD nanoparticles. 
Results: We observed that rhodamine, delivered by αvβ3-rhodamine NP, was incorporated into M2 
tumor promoting macrophages through both phagocytosis-independent and dependent mechanisms, 
while NP uptake in tumor suppressing M1 macrophages was almost exclusively through phagocytosis. In 
a mouse model of breast cancer (4T1-GFP-FL), M2-like TAMs were significantly reduced with 
αvβ3-MI3-PD NP treatment. To validate this effect was independent of drug delivery to tumor cells and 
was specific to the MYC inhibitor, mice with integrin β3 knock out tumors (PyMT-Bo1 β3KO) were 
treated with αvβ3-NP or αvβ3-MI3-PD NP. M2 macrophages were significantly reduced with 
αvβ3-MI3-PD nanoparticle therapy but not αvβ3-NP treatment. 
Conclusion: These data suggest αvβ3-NP-mediated drug delivery of a c-MYC inhibitor can reduce 
protumor M2-like macrophages while preserving antitumor M1-like macrophages in breast cancer. 










New breast cancer therapies have significantly 
improved patient outcomes over the last decade, but 
for some subtypes or advanced malignancies, there 
are limited therapeutic options. Immunotherapies 
have primarily focused on enhanced T cell activation 
and increased cytotoxicity towards cancer cells. 
However, many breast cancers have high numbers of 
tumor-associated macrophages (TAMs) which, in 
addition to promoting tumor growth, repress 
antitumor T cell responses, correlate with poor 
prognosis, and limit the efficacy of immunotherapy 
[1, 2]. Previous work has shown that macrophage 
depletion reduces tumor size in breast and other 
cancers [3]. 
Tumor-associated macrophages encompass a 
spectrum of subtypes with diverse functions, but are 
commonly divided into two broad categories: 
classically polarized M1 phenotype (antitumor) 
macrophages and alternatively polarized M2 
phenotype (protumor) macrophages. Inherently 
cleared by the macrophage monocyte phagocytic 
system (MPS), nanoparticle technologies have been 
used as macrophage imaging agents (SPIO NP) [4, 5] 
and therapeutics [6-9]. Iron oxide nanoparticles have 
been a dominant component in many of these 
nanosystems due to their ability to influence 
macrophages toward an M1 phenotype, increase 
M1/M2 ratios, and promote anti-tumor immune 
responses [10, 11]. Examples of iron oxide containing 
nanoparticles that repolarize macrophages include ex 
vivo hyaluronic acid decorated SPIO NP (HIONs) [12] 
and immune stimulatory formulations; TLR3 agonist 
poly (I:C) [13], melanin-like iron oxide NP 
(Fe@PDA-PEG) [14], photogeneration of reactive 
oxygen species [15] and iron oxide nanoparticles 
under AMF exposure [16-18]. Encapsulation of 
therapeutic cargo that inhibits proteins or genes 
specific to M2 macrophages or TAM-suppressive 
functions can further improve specificity [19]. 
In myeloid cells, the b-HLHZIP transcription 
factor c-MYC (MYC) has been shown to regulate 
macrophage inflammatory responses, macrophage 
maturation and M2 polarization, and tumor- 
promoting functions [20, 21]. Therapeutic targeting of 
MYC in TAMs could therefore reduce the ability of 
macrophages to polarize to an immune suppressive 
M2 phenotype and enhance the switch to an 
inflammatory response. Previous attempts at 
inhibiting MYC function have included anti-sense 
nucleic acid strategies [22], RNA interference [23], and 
interference with MYC-MAX dimerization and 
subsequent E-box binding using small molecules 
[24-32]. Several small-molecule inhibitors of the 
MYC-MAX interaction have been reported [24, 33-36] 
but all were challenged by rapid metabolism and poor 
bioavailability, leading to poor anti-tumor responses. 
To overcome these barriers, we used a potent small 
molecule inhibitor that we designed into a lipase- 
labile phosphatidylcholine prodrug, which enables 
stable incorporation into the phospholipid membrane 
of targeted perfluorocarbon nanoparticles [37] (See 
Supplemental Data). 
For the present experimental work, we designed 
a MYC inhibitor prodrug (MI3-PD) for 
perfluorocarbon nanoparticle delivery to M2 
macrophages through activated integrin αvβ3 with 
the intent to disrupt M2 polarization without 
compromising macrophage viability. We found that 
human breast cancer patient tumors have increased 
numbers of integrin αvβ3-positive macrophages, and 
we provide new evidence that human breast cancer 
TAMs express MYC. We also show that αvβ3-targeted 
nanoparticles at least in part, are taken up by a 
phagocytosis-independent mechanism in M2 
macrophages. In murine immunocompetent models 
of estrogen receptor positive (ER+) and triple- 
negative breast cancers, αvβ3-targeted MI3 prodrug 
nanoparticles (αvβ3-MI3-PD NP) decreased M2 
polarized TAMs in mammary fat pad tumors and 
preserved M1 TAM numbers. These data provide 
therapeutic proof of principle that inhibition of MYC 
signaling through αvβ3-targeted drug delivery of the 
small molecule MI3-PD could be used to reduce M2 
macrophages in the tumor microenvironment while 
sparing M1 antitumor macrophages. 
Materials and Methods 
Synthesis and characterization of 
αvβ3-targeted-MI3-PD NP 
αvβ3-targeted-MI3-PD perfluorocarbon NP were 
prepared as previously described and characterized 
[38] (see Supplemental Data for further discussion 
and Figure 1A). A microfluidized suspension of 20% 
(v/v) perfluorooctylbromide (PFOB, Exfluor Inc., 
Round Rock, TX, USA), 2.0% (w/v) of a surfactant co- 
mixture, and 1.7% (w/v) glycerin. The surfactant co- 
mixture of NP included: 0.15 mol% of αvβ3-PEG2000- 
PE, 4 mol% of the MI3-PD, and the balance was high 
purity egg phosphatidylcholine (PC) (Lipoid LLC, 
Newark, NJ). The surfactant components were 
combined with the PFOB, deionized water, and 
glycerin. The mixture was pre-blended (Tissumizer 
Mark II, Tekmar, Cincinnati, Ohio, USA) then 
homogenized at 20,000 psi for 4 min (M110s, 
Microfluidics Inc., Westwood, MA, USA). Control 
αvβ3-targeted nanoparticles excluded MI3-PD. 
Routine NP characterization revealed: nominal size of 





262 nm, polydispersity of 0.09, and zeta potential of 
-20 mV as shown in Figure 1B (Brookhaven 
Instruments Co, Holtsville, NY, USA). Transmission 
electron microscopy images of this nanoparticle were 
previously published [38]. 




To a solution of 4'-methyl-6-((7-nitrobenzo[c] 
[1,2,5]oxadiazol-4-yl)amino)-[1,1'-biphenyl]-3-carboxy
lic acid [39] (400 mg, 1.02 mmol, 1 eq) in anhydrous 
DMF (15 mL) was added 2-chloroethanol (76 µL, 1.12 
mmol, 1.1 eq) and K2CO3 (211 mg, 1.53 mmol, 1.5 eq). 
The reaction mixture was stirred at 80 ºC for 3 h, at 
which point TLC indicated the reaction was complete. 
The reaction was cooled to room temperature then 
carefully acidified with 1M HCl. The mixture was 
extracted with ethyl acetate (EtOAc ×2), the organic 
layers were combined, washed with water (×3), brine 
and then dried over Na2SO4. The residue was 
re-suspended in ether, vigorously stirred for 30 min, 
then the product was isolated by vacuum filtration to 
afford the title compound as a bright red solid (376 
mg, 85%): 1H (d6-DMSO) δ 2.26 (s, 3H), 3.75 (m, 2H), 
4.35 (m, 2H), 5.00 (br, 1H), 6.25 (d, J = 8.8 Hz, 1H), 7.17 
(d, J = 7.2 Hz, 2H), 7.35 (d, J = 7.2 Hz, 2H), 7.70 (d, J = 
8.0 Hz, 1H), 8.11 (m, 2H), 8.43 (d, J = 8.8 Hz, 1H), 11.04 
(s, 1H); 13C (d6-DMSO) δ 25.8, 64.2, 72.1, 108.0, 128.2, 
133.3, 133.5, 134.4, 134.6, 134.7, 137.2, 139.7, 142.2, 
142.5, 143.7, 144.4, 148.2, 149.2, 149.5, 170.3. 
MI3 was used alone as the “free drug” or 
esterified with 1-palmitoyl-2-azelaoyl phosphatidyl-
choline (fatty acid modified oxidized lipid 16:0-9:0 
COOH PC, PAzPC) through a dicyclohexyl carbo-
diimide (DCC)/4-dimethyl amino pyridine (DMAP) 
mediated coupling to produce MI3-PD (Figure 1C, D). 
The chemical structure of MI3-PD was characterized 
by MS spectrometric analysis (ESI-TOF (positive 
mode): m/z [C55H80N5O15P]+ Calculated. 082.22 Da.; 
Observed (M+H) 1083 Da. 
Characterization of the αvβ3-integring 
nonpeptide antagonist 
The αvβ3-integrin ligand (αvβ3) was a quinolone 
nonpeptide antagonist (Figure 1E) developed by 
Bristol-Myers Squibb Medical Imaging (BMSMI, US 
patent 6,511,648 and related patents) that was initially 
reported and characterized as the 111In-DOTA 
conjugate RP748 and cyan 5.5 homologue TA145 [40]. 
The specificity of the αvβ3-ligand mirrors that of 
antibody LM609 as assessed by staining and flow 
cytometry, and it has a 15-fold preference for the Mn2+ 
activated receptor (21 nM) [41]. The ligand has broad 
species cross-reactivity. Dissociation constants of the 
mimetic in humans established by BMSMI were: 1) 
αvβ3-receptor ELISA (biotin-Vn): <1 nM, 2) αvβ5 
whole cell assay: 5.4 ± 1.9 µM, 3) αvβ5-receptor ELISA 
(biotin-Vn): 4 nM, 4) α5β1 whole cell assay: > 10 µM, 
5) GP IlbIIIa PRP aggregation: > 10 µM, 6) isolated 
platelet GP IIbIIIa receptor: 5,289 µM [42]. The 
peptidomimetic was coupled via a polyethylene 
glycol spacer (PEG2000) to phosphatidyl-
ethanolamine (αvβ3-PEG2000-PE, Gift from Kereos, 
Inc, St. Louis, MO). The targeted nanoparticles (NP) 
presented ~300 ligands/particle with an IC50 of 50 pM 
for the Mn2+-activated αvβ3-integrin [43]. 
Cell lines 
The murine C57BL/6 PyMT-Bo1 luminal B 
breast cancer cell line (stably expressing GFP and 
firefly luciferase genes) was originally isolated from a 
transgenic MMTV-PyMT breast tumor, as previously 
validated and described [44]. The PyMT-Bo1 Itbg3 
knockout cell line (PyMT-Bo1 β3 KO), was created by 
CRISPR genome editing as described below. The 4T1- 
GFP-FL cell line expresses green fluorescent protein 
(GFP) and firefly luciferase (FL) and was obtained 
from the David Piwnica-Worms lab [45]. The 
MDA.MB.435 cell line was obtained from the ATCC. 
All cells were maintained at sub-confluence in DMEM 
with 10% fetal bovine serum (FBS) and 0.5% 
penicillin–streptomycin, in a humidified chamber 
under standard culture conditions. Low-passage 
stocks were used and regularly tested for 
Mycoplasma and maintenance of growth 
characteristics. Primary human umbilical vein 
endothelial cells (HUVEC) were obtained from Lonza 
(Basel, Switzerland), and express CD31, CD105, von 
Williebrand Factor VIII, and were positive for 
acetylated low-density lipoprotein uptake. HUVECs 
were grown to 70% confluence in VascuLife 
Endothelial Cell Culture Media (Lifeline Cell 
Technologies, Fredrick, MD, USA) and maintained for 
less than five passages. 
Generation of an integrin β3 (Itgb3) knockout 
breast cancer cell line 
PyMT-Bo1 Itbg3 knockout cells (PyMT-Bo1 β3 
KO) were generated using the CRISPR/Cas9 system 
of genetic engineering. This work was done through 
the Genome Engineering and iPSC center (GEiC) at 
Washington University School of Medicine (St. Louis, 
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9 of Itgb3 showed a 25 base pair deletion in one Itgb3 
allele and a 31 base pair deletion in the other Itgb3 
allele. Flow cytometry analysis of integrin β3 
demonstrates the complete loss of surface expression. 
Isolation and polarization of bone marrow 
macrophages 
To generate primary macrophages, whole bone 
marrow was extracted from the femurs and tibias of 
mice and plated in petri dishes in MEM Alpha media 
containing 10% fetal bovine serum and 50 ng/mL 
M-CSF. For macrophage polarization assays, day 3 
cultured macrophages were plated at 5x105 cells per 
well in 6-well cell culture plates and treated for 6-48 h 
depending on the assay and polarized with IFN-γ (5 
ng/mL) for M1 polarization or IL-4 (5 ng/mL) for M2 
polarization or tumor-conditioned media. Tumor 
conditioned media was generated from the murine 
breast cancer cell line PyMT-Bo1. PyMT-Bo1 cells 
were cultured for 24-48 h. Harvested media was 
diluted in MEM Alpha macrophage media at a 1:2 
ratio and M-CSF was maintained at 50 ng/mL. 
In vitro nanoparticle binding assay 
Cells treated with 50 pM αvβ3-targeted NP, 50 
pM non-targeted NP, or 50 fM of fluorescent 1 µm 
carboxylate-modified latex beads (L4655, Sigma- 
Aldrich). Cells were incubated for 3 h at the 
appropriate temperature (37 °C or 4 °C) with 
continuous shaking. After 3 h, each well was washed 
3 times with PBS, and removed with 0.5% trypsin. 
Cells were analyzed by flow cytometry analysis on a 
BD LSRFortessa (BD Biosciences) and data analysis 
was performed with FlowJo software version 10.1 
(Tree Star). 
RNAseq data acquisition and analysis 
RNAseq normalized data were downloaded 
from the Gene Expression Omnibus database [46]. 
Whole-tissue breast cancer RNAseq data were 
obtained from the GSE100925 as normalized FPKM 
[47]. RNAseq data from breast cancer TAMs (CD45+ 
CD3/56/19-CD11b+CD14+CD163+) and circulating 
monocytes (CD45+, CD3/CD19/CD56-, HLA-DR+) 
were downloaded from the GSE117970 dataset as 
normalized CPM (described in the original work) [47]. 
Conversion of gene identifiers between entrez gene ID 
and official gene name was run on the Database for 
Annotation, Visualization and Integrated Discovery 
[48, 49] and verified on the individual gene’s Uniprot 
entry. The corresponding gene list is shown in 
supplemental Table S1. Prism8 (GraphPad) was used 
to generate plots and calculate Pearson’s correlation 
coefficient r and p values. 
 
 
Figure 1. Development of αvβ3 targeted MI3 prodrug perfluorocarbon nanoparticles (PFC). (A) PFC nanoparticles deliver MI3 prodrug through a 
contact-facilitated drug delivery mechanism. (B) Analysis of the average PFC nanoparticle diameter, polydispersity and zeta potential (C) MYC/MAX dimerization inhibitor MI3 
prodrug (D) MYC inhibitor MI3 (E) αvβ3-integrin targeting ligand. 





Pharmacological inhibition of phagocytosis 
For pharmacological inhibition of phagocytosis, 
macrophages were pretreated for 1 h with 5 μM of the 
phagocytic inhibitor Cytochalasin D (CytoD), (sc- 
201442, Santa Cruz Biotechnology), which inhibits 
actin polymerization on the plasma membrane. 
Alternatively, macrophages were pre-cooled at 4 °C 
for 1h, which also inhibits actin dynamics [50, 51]. 
After 1 h, cells were then treated with either NP or 
latex phagocytic beads, at the appropriate culturing 
conditions (in the presence of CytoD, or at 4 °C). 
In vitro MI3-PD dosing 
Macrophages were cultured for 3 days as 
described above. Cells were then trypsinized and 
plated onto petri dishes with MEM Alpha media and 
50-100 ng/mL M-CSF and polarized with IFNγ (5 
ng/mL), IL-4 (5 ng/mL) or tumor-conditioned media 
(1:2). The following day, cells were dosed with MI3 
prodrug and fresh media containing M-CSF with 
cytokines or tumor conditioned media (TuCM). After 
48 h cells were assessed by MTT or RNA was 
harvested with the RNeasy kit (Qiagen). 
MTT viability assay 
The MTT viability assay was performed as 
described previously [52]. For post-polarization 
assays, cytokine (IL-4, IFNγ, TuCM) was added 24 h 
prior to the addition of drug or nanoparticle. Pre- 
polarization assays were treated with drug or 
nanoparticle 1 h prior to the addition of polarizing 
cytokines or tumor conditioned media. Signal 
intensity is reported as OD570. Cell viability was 
assessed at 6-48 h. 
Real-time quantitative PCR (qPCR) analysis 
Total RNA from cells was isolated with the 
RNeasy Mini Plus kit (Qiagen). Complementary DNA 
was made using the (qScript cDNA Synthesis Kit, 
Quanta). qPCR was performed using PerfeCTa SYBR 
Green FastMix (Quanta), with mouse-specific primers 
for mRNA genes of interest: Actin, C-myc, Max, 
Akap12, Wnt5a, Maoa, Mrc1, Myc, and Pcsk5, analyzed 
using the ∆∆Ct method. The primer sequences are 
shown in supplemental Table S2. 
Arginase 1 – yellow fluorescent protein (YFP) 
assay 
Macrophages were isolated from mice 
genetically engineered to express the YFP protein 
downstream of the endogenous stop codon of the 
Arginase 1 gene (Jackson Labs, B6.129S4-Arg1tm1Lky/J) 
[53]. Bone marrow macrophages were cultured as 
described, plated in MEM Alpha media containing 50 
ng/mL M-CSF and 0.5 ng/mL of IL-4. After 24 h of 
polarization, cells were treated with MI3 prodrug for 
48 h and Arg1 expression read by YFP expression was 
assessed by flow cytometry. 
Animals Use 
Animal studies were approved by and 
performed in accordance with the guidelines 
established by the Washington University 
Institutional Animal Care and Use Committee 
(IACUC). All mice were obtained from The Jackson 
Laboratory and were housed according to the 
guidelines of the Division of Comparative Medicine, 
Washington University School of Medicine. 
Murine cancer models and therapeutic dosing 
To establish orthotopic mammary fat pad (MFP) 
tumors, 0.1×106 PyMT-Bo1 β3 KO and 4T1-GFP-FL 
tumor cells were resuspended in 50 µL PBS and 
implanted into MFP tissue of 7-8 week-old female 
C57BL/6 mice. MI3-PD encapsulated in αvβ3-NP was 
dosed at 4.5 mg/kg per injection with 3 nanoparticle 
injections per experiment. 
Bioluminescence imaging (BLI) analysis 
In vivo BLI was performed on IVIS50 
(PerkinElmer, Waltham, MA) as previously described 
[44]. Total photon flux (photons/sec) was measured 
from fixed regions of interest (ROIs) using Living 
Image 2.6. Investigators were blinded to treatment 
groups during all BLI analyses. 
Flow Cytometry of mammary fat pad tumors 
Tumors were harvested, minced and incubated 
in 1X collagenase for 1 h at 37 °C shaking. 
Collagenased tumor was put through a 70 µm cell 
strainer, washed in media, and cell counted. Cells 
were prepped for flow cytometry by aliquoting 3 
million cells into wells in a 96-well v-bottom plate. 
Cells were spun at 12000 RPM for 5 min at 4 °C, media 
removed and incubated for 20 min with Fc block. 
After FACS Buffer (PBS, 5% FBS, EDTA) wash, cells 
were incubated with antibody for 20 min, washed 
twice in FACS buffer and resuspended for flow 
cytometry on the BD X-20Fortessa. The antibody 
panel used for flow cytometry is available in 
supplemental Table S3. 
Statistical analysis 
All data is shown as mean with error bars 
representing SEM. All sample sizes reported in the 
study are the minimum number of samples. For 
animal studies, sample sizes were estimated 
according to our previous experience. Statistical 
differences were analyzed using either a two-tailed 
t-test, ANOVA with Tukey’s test for a posteriori 
(post-hoc) multiple comparisons or a two-tailed 





unpaired t-test with Bonferroni correction for a priori 
comparisons between a control group and 
experimental treatment groups of interest. 
Assumptions for ANOVA and t-test (independent 
samples, approximately normal distributions) for 
samples n>5 were sufficiently met, or used if a 
random sample of n≤5 were selected from an 
approximately normally distributed population. Non- 
normally distributed data were analyzed using a two- 
tailed Mann–Whitney U-test or a two-tailed Wilcoxon 
signed-rank test for matched-pairs. All tests were 
considered significant at P≤0.05. Data analyses were 
performed with Prism 8 (GraphPad Software). 
Results 
Integrin β3 is expressed on human breast 
cancer-associated macrophages and can be 
targeted by nanoparticles in mice 
We have previously shown that integrin β3 is 
expressed on tumor-infiltrating M2 phenotype 
macrophages in mice [44]. To determine whether 
integrin β3 is also expressed on breast cancer- 
associated macrophages, human tissue arrays of non- 
malignant and breast cancer tissues were assessed for 
infiltration of activated macrophage (CD68+) and 
expression of integrin β3 (CD61+). We found that the 
percent of CD68+ macrophages was significantly 
increased in human breast cancer compared to normal 
tissue. Further, 64% of CD68+ TAMs also expressed 
integrin β3 in breast cancer tissue as compared to 20% 
in normal breast tissue, indicating the potential to 
target these cells with αvβ3-NP-mediated drug 
delivery (Figure 2A). 
Surface integrin β3 expression was evaluated by 
flow cytometry on tumor and endothelial cell lines 
using antibodies against murine integrin β3 (CD61) or 
activated human αvβ3 (LM609). As previously 
published, high levels of activated human αvβ3 were 
observed in MDA.MB.435 melanoma cells and 
HUVEC endothelial cells as indicated by the mean 
fluorescence intensity (MFI) of 42 and 27 respectively 
(Figure 2B). Integrin β3 expression was also observed 
in the murine estrogen receptor positive (ER+) breast 
cancer cell line PyMT-Bo1 but at relatively lower 
levels (17 MFI, Figure 2B). In vitro binding of αvβ3-NP 
labeled with rhodamine (αvβ3-rhodamine NP) 
revealed αvβ3-rhodamine NP uptake was similar to 
the amount of surface integrin expression observed by 
flow cytometry (CD61 or LM609, Figure 2B). 
 We have previously shown that αvβ3-NP bind 
to the tumor endothelium in vivo [54]. We next 
assessed the ability of αvβ3-rhodamine NP to bind 
myeloid cells in vivo. Non-tumor bearing mice were 
injected with αvβ3-rhodamine NP or PBS. Bone 
marrow was harvested and analyzed by flow 
cytometry for myeloid cell marker CD11b and 
rhodamine fluorescence 3 h after inoculation. 
Rhodamine-positive CD11b+ cells were not detected 
in PBS treated mice (<1%) but were present in mice 
injected with 50 µl or 100 µl αvβ3-NP. Rhodamine+, 
CD11b+ bone marrow cells correlated with the 
amount of αvβ3-NP injected at 35% and 49% 
respectively (Figure 2C). These data indicate αvβ3- 
targeted nanoparticles can bind to a significant 
number of CD11b-expressing myeloid cells in bone 
marrow in vivo. 
 Integrin αvβ3-targeted nanoparticles can 
deliver rhodamine payload to M2 
macrophages in part through a 
phagocytosis-independent mechanism 
Next, we assessed integrin β3 expression on in 
vitro cultured bone marrow macrophage populations 
(BMMs): unpolarized macrophages (M0, M-CSF 
alone), M1 (classically polarized using M-CSF+IFNγ), 
M2 (alternatively polarized using M-CSF+IL-4). By 
flow cytometry, integrin β3 expression was increased 
14-fold in M2 macrophages as compared to 
expression in M1 macrophages and 7-fold as 
compared to M0 macrophages (381, 27 and 57 MFI 
respectively, Figure 3A). To confirm that the αvβ3 
targeting ligand used in these nanoparticles bind to 
M2 macrophages, we used an activated αvβ3 specific 
targeting ligand conjugated to a fluorescence probe 
and incubated with bone marrow macrophages 
isolated from WT or β3 deficient mice [55]. The αvβ3 
targeting probe showed a non-specific 4-fold increase 
in binding to β3 KO M2 macrophages compared to the 
unstained control while the binding was increased 
12-fold in WT M2 macrophages (Figure S1). We next 
incubated bone marrow derived macrophages with 
αvβ3-rhodamine NP and found that greater than 70% 
of cells in all three subsets of macrophages (M0, M1 
and M2) were rhodamine positive. 
Typically, phagocytosis refers to the engulfment 
of particles of 500 nm of diameter or larger, achieved 
through reorganization of the actin cytoskeleton and 
lipid membrane. In professional phagocytic cells such 
as macrophages, this follows the activation of specific 
receptors, such as FcR. Macrophages can phagocytose 
polymeric particles, requiring strategies to prevent 
lysosomal degradation of cargo drugs. To assess 
whether αvβ3-rhodamine NP were taken up 
exclusively by phagocytosis or a non-phagocytic 
mechanism like contact facilitated drug delivery 
CFDD (Figure 3B) [37, 56-59], we evaluated uptake in 
the presence of phagocytosis inhibitors. 






Figure 2. Human breast cancer tumor-associated macrophages express β3 integrin. (A) Immunofluorescence of CD68+ (n=10, n=108) and CD68+, CD61+ (n=10, 
n=106) macrophages in human non-malignant (blue) and malignant breast tissue (red), respectively (***P≤0.001). (B) Flow cytometry analysis of β3 integrin expression (blue) and 
nanoparticle uptake (rhodamine+) by murine breast cancer cell line (PyMT-Bo1, MFI 17), human melanoma (MDA.MB.435, MFI 27) and human endothelial (HUVEC, MFI 42) cell 
lines in vitro. Duplicate biologic replicates were preformed with representative images shown. (C) Flow cytometry analysis of bone marrow from PBS or αvβ3-rhodamine treated 
mice (n=3). MFI: median fluorescent intensity. 
 
Cytochalasin D inhibits phagocytosis and 
macropinocytosis by disrupting actin polymerization. 
There was a marked cell number reduction in 
rhodamine uptake after incubation with αvβ3- 
rhodamine NP and cytochalasin D in the M1 
macrophages of 4% and in the M0 macrophages of 
13%; whereas, rhodamine cellular uptake by 50% was 
noted after incubation with αvβ3-rhodamine NP and 
cytochalasin D in the M2 macrophages (Figure 3C). 
These data suggest that M0, M1 and M2 macrophages 
can phagocytose αvβ3-rhodamine NP, however, of 
the macrophage subsets evaluated, the M2 
macrophages, which have the highest αvβ3 
expression, have the greatest ability to take up cargo 
through a phagocytosis-independent mechanism. 
MI3 prodrug reduces expression of MYC 
regulated genes with known roles in 
macrophages polarity 
MYC is an oncogene frequently expressed in 
cancer cells. MYC expression has more recently been 
reported in tumor-associated macrophages (TAMs) 
[60]. To determine whether our targets MYC and 
MAX were expressed by macrophages in human 
breast cancer, publicly available RNAseq data sets on 
human breast cancer TAMs [47] were analyzed for 
MYC and MAX levels. MYC and MAX RNA were 
detected in circulating breast cancer monocytes 





(KRT7+, CD11b+, CSF1R+), whole breast cancer tissue 
(KRT7+, CD11b+, CSF1R+), and isolated breast cancer 
tumor infiltrating macrophages (KRT7 negative or 
low, CD11b+, CSF1R+), supporting a potential role for 
MYC in human TAMs (Figure 4A). Evaluation of 
murine BMM also demonstrated that Myc expression 
was upregulated upon IL-4-induced M2 polarization 
when normalized to M0 mRNA, whereas Myc 
expression was decreased by IFNγ-induced M1 
polarization. Collectively, we found that M2 polarized 
BMMs (IL-4-induced, or tumor conditioned media 
induced) had increased expression of Myc mRNA as 
compared to M0 or IFNγ-induced M1 macrophages 
(Figure 4B). 
To test the ability of our MYC-MAX 
dimerization inhibitor MI3 prodrug (MI3-PD) to 
reduce expression of known MYC-regulated genes 
involved in M2 polarization, mRNA expression of 
MI3-PD treated BMMs was assessed [60]. MYC 
inhibition of early macrophages prior to IL-4-induced 
M2 polarization decreased known MYC regulated 
genes, including the M2 markers Maoa and CD206 
(Mrc1) (Figure 4C). MI3-PD inhibition of more 
established M2 macrophages (after IL-4 polarization) 
significantly decreased expression of an alternative 
set of MYC regulated genes, including Akap12 and 
Wnt5a. MI3-PD had no effect on expression of Myc or 
Pcsk5, a gene regulated independent of MYC (Figure 
4D) [60]. Finally, macrophages were polarized using 
breast cancer tumor-conditioned media (TuCM) to 
evaluate the effects of MYC inhibition on 
macrophages in a breast cancer context. MYC 
inhibition of BMM polarization with TuCM decreased 
Akap12 and Wnt5a, an effect similar to what we 
observed in IL-4-polarized M2 macrophages treated 
with MI3-PD (Figure 4E). 
We next assessed the ability of MI3-PD to reduce 
protein expression of well-known M2 polarity marker 
Arginase I (ARG1). The transgenic B6.129S4- 
Arg1tm1Lky/J mice (ARG1-YFP) express yellow 
fluorescent protein (YFP) downstream of the Arg1 
gene, reporting in vivo on the level of ARG1 
 
 
Figure 3. Nanoparticle delivery of MI3 prodrug occurs in part through a non-phagocytic mechanism in M2 macrophages. (A) Flow cytometry analysis for β3 
integrin expression and the percent of cells positive for rhodamine following in vitro incubation with αvβ3 rhodamine labeled nanoparticles (NP) in M0 (blue, MFI 57), M1 (green, 
MFI 27) and M2 (purple, MFI 381) macrophage subsets. (B) Nanoparticles can deliver drug through a contact-mediated drug delivery mechanism or non-specific phagocytosis. 
Contact-facilitated drug delivery avoids sequestration and degradation in the endocytic pathway. (C) Flow cytometry analysis of the percent of cells positive for rhodamine in the 
presence (orange) or absence (blue) of phagocytosis inhibitor Cytochalasin D after in vitro incubation with αvβ3-rhodamine labeled nanoparticles as compared to vehicle treated 
controls (red). Representative experiments are shown. Biologic replicates were completed in triplicate for all experiments. 





biosynthesis. To validate in live cells the effect of MYC 
inhibition, BMM were isolated from ARG1-YFP, 
cultured and polarized with TuCM in vitro, and then 
treated with MI3-PD [53]. MI3-PD inhibition reduced 
arginase expression by 35%, compared to vehicle 
treated M2 BMMs (Figure 4F). Interestingly, MI3-PD 
had no effect on macrophage viability in TuCM 
polarized macrophages, or IFNγ-polarized M1 
macrophages in vitro (Figure 4G). 
 
 
Figure 4. MI3 prodrug treatment reduced expression of MYC regulated genes involved in alternative activation of M2 macrophages. (A) Quantification of 
MYC and MAX expression in human breast cancer tissues from by RNAseq analysis. (B) qPCR of Myc mRNA expression in murine bone marrow macrophage subsets M0, M1 
(IFNγ), M2 (IL-4) and tumor conditioned media (TuCM) polarized macrophages (6 h). Quantitative PCR of known MYC regulated genes in (C) M0 macrophages treated with IL-4 
and MI3 prodrug (MI3-PD, 6 h), (D) established IL-4 M2 macrophages and (E) established tumor TuCM polarized macrophages treated with MI3-PD (24 h) post polarization. (F) 
Flow cytometry of Arg1-YFP reporter macrophages polarized with TuCM and treated with MI3-PD (48 h). (G) MTT viability assay for macrophages treated with MI3-PD (48 h). 
Data shown is the average of two biologic replicates. (H) Correlation of CD47 and MYC expression in human breast cancer by in silico analysis of RNAseq data sets. (I) RNAseq 
data from murine breast cancer TAMs (DAPI−CD45+CD11b+Ly6G−Ly6C−F4/80+, GSE104765, n=12) was assessed and normalized values as presented in the original paper, were 
tested for correlation. (J) Cd47 qPCR of murine M2 (IL-4) macrophages treated with MI3-PD (24 h). All qPCR experiments were shown as representative experiments and 2-3 
biologic replicates were performed for each. P-values are denoted as follows: *P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001. ND: not detectable, ns: not significant. 






Figure 5. αvβ3-targeted MYC inhibitor MI3 loaded nanoparticles decreased M2 tumor-associated macrophages in the 4T1-GFP-FL (4T1) murine breast 
cancer model. (A) 4T1 cells were implanted into the mammary fat pad (MFP, day 0) and mice were given three doses of PBS or αvβ3-MI3-PD nanoparticles (NP, n=6/group). 
(B) Bioluminescence imaging (BLI) of in vivo tumor growth (*P≤0.05) (C) Tumor weight at study endpoint (day 16, n=5 mice/group). Flow Cytometry of (D) GFP+ tumor cells, 
(E) Tumor-associated macrophages (TAMs) per CD45+ cells and (F) M2-like and M1-like macrophages per total TAMs, isolated from MFP tumors at day 16 (n=5/group, 
*P≤0.05). (G) Mouse weight during treatment. (H) Complete blood counts at study endpoint. NP: nanoparticle; WBC: white blood cell; ns: not significant. 
 
CD47 is a key receptor necessary for cells to 
avoid the immune system, often referred to as the 
“don’t eat me” signal. Recent work has shown that 
MYC can regulate CD47 expression in tumor cells, 
and that anti-CD47 antibody treatment of tumors 
increases the number of M1 macrophages in the 
tumor microenvironment [61, 62]. We found through 
in silico assessment of RNAseq data sets that CD47 
expression correlated with MYC expression in human 
breast cancer circulating monocytes, whole breast 
tumors, human breast cancer TAMs [47], and mouse 
mammary fat pad tumor TAMs [63] (Figure 4H,I). 
Notably, treatment of M2 macrophages with MI3-PD 
significantly reduced CD47 expression as compared to 
vehicle treated cells (Figure 4J). Taken together, these 
data show that MI3-PD treatment reduced expression 
of MYC-regulated genes in protumor M2 
macrophages in vitro. 
Integrin αvβ3-targeted MI3-PD nanoparticles 
reduce mammary fat pad tumor-associated 
macrophages in vivo 
When applied systemically, MYC inhibitors are 
quickly degraded in blood, leading to reduced drug 
bioavailability [36, 64]. Encapsulation within 
nanoparticles could increase efficacy by enhancing 
stability in circulation, increasing the amount of drug 
membrane payload delivered directly to target cells, 
and reducing off-target effects and toxicity. To 
evaluate whether αvβ3-MI3 PD nanoparticles were 
effective in vivo, mice bearing mammary fat pad 
(MFP) tumors were established, using an aggressive 
triple-negative murine breast cancer line 4T1-GFP-FL 
(BALB/C) that expresses integrin αvβ3 (Figure S2). 
Mice were given three doses of PBS or αvβ3-MI3-PD 
NP and tumors were evaluated by flow cytometry at 





study endpoint. Early stage tumors were assessed due 
to the large number of TAMs and the presence of both 
M1 and M2 macrophage subsets, compared to later 
stage tumors where M2 subsets predominate. We first 
assessed the effect of αvβ3-MI3-PD NP treatment on 
tumor growth by bioluminescent imaging (BLI) and 
tumor weight. Tumor growth at the early time point 
as measured by BLI (Figure 5B) and tumor weight at 
endpoint (Figure 5C) was similar between PBS and 
αvβ3-MI3-PD NP treatment groups. Following 
collagenase digestion, tumor composition was 
evaluated by flow cytometry. Analysis of tumor cells 
(GFP) showed there was no significant difference 
between control and treatment groups (Figure 5D). 
The percent of tumor-associated macrophages (TAMs: 
CD45+, CD11b+, GR1-, F4/80+) per total CD45+ cells 
within the MFP tumors was similar between 
treatment groups (Figure 5E). However, the percent of 
protumor M2 TAMs (CD45+, CD11b+, GR1-, F4/80+, 
MHCII low, CD206 high) was significantly decreased 
(14%) in αvβ3-MI3-PD NP treated mice, as compared 
to PBS (Figure 5F). Moreover, the percentage of 
antitumor M1 TAMs (CD45, CD11b, GR1-, F4/80+, 
MHCII high, CD206 low) was significantly increased 
(14%) in MFP tumors of αvβ3-MI3-PD NP compared 
to PBS treated mice (Figure 5F, Figure S3). For toxicity 
assessment, there were no differences between groups 
in the percent change in body weight, and for 
complete blood counts (CBC), including white blood 
cells, neutrophils, and platelets (Figure 5G,H). These 
data suggest that αvβ3-MI3-PD NP changed the 
composition of breast cancer tumor-associated 
macrophages, biasing towards low M2 TAMs, while 
inducing little systemic toxicity. 
αvβ3-MI3-PD nanoparticles do not directly 
target tumor cells to decrease M2 
macrophages in breast tumors 
 The reduction in M2 macrophages in our 4T1 
breast tumors treated with αvβ3-MI3-PD NP could be 
explained, theoretically, either by direct effects on 
αvβ3+ macrophages by MI3, as shown in vitro, or by 
indirect effects of MYC inhibition in the αvβ3+ 4T1 
cancer cells. In addition the 4T1 model has a lower 
M2/M1 ratio compared to the PyMT breast cancer 
models, which could underestimate the effect of M2 
targeted agents. Therefore, we next evaluated αvβ3 
directed MI3-PD NP therapy in a second breast cancer 
model, PyMT Bo1, which we engineered to lack 
tumoral β3. We selected PyMT-Bo1, which is a 
C57B/6 syngeneic ER+ luminal B type breast cancer 
cell line that expresses αvβ3 in vivo (Figure 6A) and 
has a higher M2/M1 ratio than 4T1 cells in vivo. We 
used the CRISPR/Cas9 system to genetically disrupt 
β3 expression (Figure 6B) and established PyMT-Bo1 
β3 knockout (KO) MFP tumors and treated with the 
same dosing strategy as the 4T1 model (Figure 6C). 
We selected an ER+ luminal B type breast cancer cell 
line PyMT-Bo1 as a second immunocompetent breast 
cancer model. Although PyMT-Bo1 cells express 
relatively low levels of β3 integrin compared to 
endothelial cells (Figure 2B), we have observed 
upregulation of β3 expression in vivo (Figure 6A, 
Figure S4A) and therefore used the CRISPR/Cas9 
system to genetically disrupt β3 expression (Figure 
6B). We established PyMT-Bo1 β3 knockout (KO) 
MFP tumors and treated with the same dosing 
strategy as the 4T1 model (Figure 6C). To demonstrate 
that macrophage effects were specific to 
MI3-PD-mediated MYC inhibition, rather than due to 
non-specific nanoparticle-binding effects, mice were 
treated with PBS, drug-free αvβ3-NP, or αvβ3-MI3- 
PD NP. In this experiment, bioluminescent imaging 
(BLI) was used to assess the presence of cancer cells 
expressing firefly luciferase, as opposed to non- 
luciferase expressing host cells, within the tumor. By 
this measure, tumor burden significantly decreased 
with αvβ3-MI3-PD NP therapy, as compared to PBS 
or αvβ3-NP treated control groups (Figure 6D). 
Tumor weight was not changed between treatment 
groups (Figure 6E). The similar tumor size could be 
due to an influx of immune or other cell types within 
the αvβ3-MI3 NP treated tumor or because tumors 
were harvested at early stages. 
We further evaluated tumor composition by 
flow cytometry and found no significant difference in 
the number of tumor cells as a percent of total cell 
number (Figure 6F). As with the 4T1 experiments, the 
overall number of TAMs (CD45+, CD11b+, GR1-, 
F4/80+) per CD45+ cells was not different between 
treatment groups (Figure 6G), but the composition of 
macrophage subsets were. There was a significant 
decrease (18%) in the percent of M2 TAMs (CD45+, 
CD11b+, GR1-, F4/80+, MHCII low, β3 integrin high) 
and a significant increase (16%) in the percent of M1 
TAMs (CD45+, CD11b+, GR1-, F4/80+, MHCII high, 
β3 integrin low) with αvβ3-MI3-PD NP therapy 
(Figure 6H, Figure S4B). There was no change in M2 
and M1 ratios in the PBS and αvβ3-NP control groups, 
indicating this effect was not due to the nanoparticle 
components or the targeting ligand (Figure 6H). 
Further, there was no change in MDSC or T cell 
populations with αvβ3-MI3-PD NP treatment (Figure 
S5). The toxicity assessments of percent change in 
mouse weight and blood counts, circulating 
neutrophils, white blood cells, or platelets remained 
the same between treatment groups αvβ3-MI3-PD NP 
treatment, as compared to the controls (Figure 6I, J). 
To evaluate whether non-targeted MI3-PD 
nanoparticles (MI3-PD NP) could reduce tumor 





burden, we treated mice with PyMT-Bo1 β3 KO MFP 
tumors with PBS, MI3-PD NP or αvβ3-MI3-PD NP. 
Tumor burden was reduced (P<0.05) in the targeted 
MI3-PD nanoparticle group but not decreased 
(P>0.05) with non-targeted MI3-PD NP, suggesting 
the reduction in tumor burden as assessed by 
luciferase expression in tumor cells was a result of 
targeted delivery of MI3 prodrug (Figure 6K). Tumor 
weight was unchanged between treatment groups 
similar to our prior results in the 4T1 and PyMT 
experiments (Figure 6L). Tumor weight is comprised 
of a dynamically changing mixture of inflammatory 
cells, edema, fibrosis, and necrosis as well as 
malignant cells, which themselves occupy only a 
fraction of the volume [65]. Together, these data 
suggest that down modulation of protumor M2 
macrophages by αvβ3-MI3-PD NP decreased (P<0.05) 
tumor activity in both an ER+ a triple negative breast 
cancer model two mouse genetic backgrounds 
without any hematological toxicity. 
Discussion 
Tumor-associated macrophages (TAMs) 
promote tumor growth and metastasis while also 
reducing the effectiveness of chemotherapy and 
immunotherapy. We and others have shown that 
murine protumor M2 macrophages have increased 
MYC and integrin αvβ3 expression. We reported that 
integrin αvβ3-expressing M2 macrophages promote 
breast cancer tumor growth in preclinical models [44], 
so we proposed a two-step therapeutic approach 
using a small molecule inhibitor to MYC-MAX by a 
vitronectin peptidomimetic targeting antagonist to 
the activated form of integrin αvβ3. We show for the 
first time that TAMs from human patient breast 
cancers express integrin αvβ3 and they also express 
MYC. Although MYC is an important target in tumor 
cells, MYC has not been therapeutically targeted in 
tumor-associated macrophages in vivo. We found that 
MYC inhibitor MI3, delivered through αvβ3-targeted 
NP, reduced M2 macrophages while preserving 
beneficial M1 macrophages in vivo. These effects were 
observed in two mouse models of ER+ and triple 
negative breast cancer in two animal backgrounds. 
MYC is expressed in human and mouse macrophages 
cultured in vitro, but MYC expression in breast cancer 
TAMs has not been explored. TAM populations often 
consist of a mixture of tissue resident macrophages 
and recruited monocytes. By RNAseq analysis of 
published data sets, we found that circulating 
monocytes and tumor-associated macrophages from 
breast cancer patients express MYC. Macrophages 
cultured in tumor conditioned-media also 
upregulated Myc, at similar levels to those induced 
during M2-polarization by IL-4. These data provide 
new support for the role of MYC in breast cancer 
TAMs, and highlight the therapeutic potential of 
targeted drug delivery against protumor M2 TAMs. 
Interestingly, MYC expression in tumor cells also 
promotes breast cancer progression, indicating that 
anti-MYC therapy could have compounding 
antitumor benefits, which are currently under 
investigation. 
MYC can act as an amplifier of multiple 
signaling pathways, regulating the expression of a 
number of genes, which can be used as a functional 
marker for MYC/MAX activity. Treatment of murine 
peritoneal macrophages and human monocytes with 
MYC/MAX inhibitor 10058-F4 (MI1) in vitro 
decreased genes known to be involved in alternative 
M2 polarization [60]. Some studies have suggested 
that the differences in the tissue origin of TAMs 
populations may result in different functions while 
others, indicate microenvironmental cues educate 
these TAMs towards a similar phenotype [66]. We 
therefore investigated the role of MYC in bone 
marrow macrophages (BMM), polarized towards an 
M2 phenotype with IL-4 or with media conditioned 
by a breast cancer cell line. We found that treatment of 
BMM with MI3 prodrug, which has a longer 
intracellular half-life than previous MYC inhibitor 
MI1 [39, 67], inhibited a similar set of genes important 
in M2 polarization (Maoa, Akap12, Wnt5a, and Mrc1). 
Moreover, we show new data indicating that the 
timing of MYC inhibition relative to addition of the 
polarizing stimulus can affect the transcription of 
different sets of MYC target genes. Downregulation of 
the key markers of M2 polarization, Cd206 and 
arginase 1, suggests that nanoparticle-mediated drug 
delivery of MI3 MYC inhibitors could reduce M2 
macrophage polarization and function in vivo [68]. 
Furthermore, we found that MYC inhibition can 
decrease Cd47 in tumor-associated macrophages in 
vitro. CD47 has emerged as an important checkpoint 
for the immune system [69]. Tumor cells upregulate 
CD47, known as the “don’t eat me” signal, to escape 
recognition and clearance by immune cells including 
macrophages. MYC has been shown to regulate CD47 
expression in some tumor types [61]. Inhibition of 
CD47 on tumor cells promotes M1 macrophages in 
the tumor microenvironment, although it is unclear 
whether this occurs through increased recruitment of 
M1 macrophages or reprogramming of existing 
macrophages toward an M1 phenotype [62]. We also 
found that MYC expression correlates with CD47 
expression in human whole breast tumor tissue, 
circulating monocytes, and tumor-associated 
monocytes in patients with breast cancer, indicating 
that MYC regulation of CD47 may be conserved 
within breast cancer TAMs as well. We hypothesize 





that MYC downregulation of Cd47 may contribute to 
the M1/M2 shift in our models of breast cancer. 




Figure 6. MYC inhibitor MI3 reduces pro-tumoral M2-like macrophages and enhances M1-like macrophages in an in vivo breast cancer model. (A) Integrin 
β3 expression on PyMT-Bo1 tumor cells isolated from breast cancer metastases in bone. (B) Flow cytometry of β3 expression (orange) (C) β3 KO cells were implanted into the 
mammary fat pad (MFP) of mice that were treated with PBS, no drug αvβ3-nanoparticles (NP) or αvβ3-MI3 prodrug nanoparticles (αvβ3-MI3-PD NP, n=4/group). (D) 
Bioluminescence imaging (BLI) of in vivo tumor growth (*P≤0.05). (E) Tumor weight at day 16. Flow cytometry analysis of (F) GFP+ tumor cells (G) Tumor associated 
macrophages (TAMs: CD45+, CD11b+, Gr1-, F4/80+) per CD45+ cells and (H) M2-like (MHCII low, β3 integrin high) and M1-like macrophages (MHCII high, β3 integrin low) 
per TAMs (n=2-3 mice/group) in day 16 MFP tumors. (I) Mouse weight during treatment. (J) Complete blood counts at study endpoint (n=3-4/group). (K) BLI of in vivo tumor 
burden (n=5/group). (L) Tumor weight at day 15. *P≤0.05, **P≤0.01, ns: not significant; WBC: white blood cell. 





Direct macrophage targeting with 
nanotechnologies, has focused on exploitation of the 
surface macrophage activation markers CD44 and 
CD206, which have a higher expression on M2 but are 
also expressed on M1-type cells [70-73]. Our group 
has previously shown that integrin αvβ3 is not 
expressed at high levels on unpolarized myeloid cells 
or M1 macrophages, but is upregulated on M2 
macrophages; furthermore, we found that integrin β3 
plays a functional role in maintaining macrophage 
homeostasis and serves as a negative inhibitor for M2 
function [44]. Here, we show that integrin β3 is 
expressed on the majority of TAMs in human breast 
cancer patient tissues and we use αvβ3-targeted 
nanoparticle technology to deliver our MI3 prodrug in 
vivo. 
To demonstrate NP targeting of MYC in M2 
macrophages while preserving M1 macrophages, we 
evaluated the effects of our NPs using small early 
stage tumors, which in our hands, have a large 
immune component including both M1 and M2 
macrophages. We found that αvβ3-MI3-NP 
significantly decreased M2 macrophages and 
increased M1 macrophage numbers in two breast 
cancer models. Tumor weight was not changed at the 
time of analysis although changes in bioluminescent 
activity were observed. We demonstrated a significant 
decrease in tumor burden by BLI with αvβ3-MI3-PD 
treatment. This reduction was not present in the 
αvβ3-NP or MI3-PD nanoparticles control groups. 
There are several challenges to evaluating tumor 
burden as tumor weight may not reflect changes in 
the cellular composition of a tumor. Bioluminescence 
imaging represents tumor activity in vivo without 
mechanical tissue disruption and may be a better 
reflection of real time tumoral changes; however BLI 
depends on ATP, oxygen and luciferin availability. 
Interestingly, there is clinical evidence that immune 
therapies often change the tumor cellular composition 
and metabolic uptake as measured by FDG PET, 
before eventually reducing tumor size [74]. Radiology 
societies have modified the criteria for evaluating 
treatment response in solid tumors to account for 
unchanged or pseudo-progression of tumor volumes 
due to the influx of inflammatory cells [75]. Clinical 
studies have shown that immune checkpoint 
inhibitors are less effective in some breast cancer 
subtypes like ER+ cancers. It is thought that 
macrophages play a large functional role in immune 
suppression in breast cancer. Clinical testing of 
generalized macrophage inhibitors are underway but 
there are concerns for inhibiting anti-tumor M1 
phenotype macrophages as well. Our data suggest 
that patients with higher levels of TAMs could derive 
more benefit from immune checkpoint therapies 
when combined with macrophage-targeted therapies 
such as αvβ3-MI3-PD NP. It is possible that 
αvβ3-MI3-PD NPs had less impact on tumor cell 
burden as measured by BLI in the 4T1 triple negative 
breast cancer compared with the ER+ PyMT-Bo1 
breast cancer, because there are significantly lower 
percent of M2-type TAMs in the 4T1 model as 
compared to the PyMT-Bo1 control tumors. 
In macrophages, activation of specific receptors 
is required for phagocytosis and includes opsonin, 
scavenger and toll like receptors, among others [76]. 
Receptor expression can be specific to macrophage 
subtype and determines the type of particles (bacteria, 
parasites, cell debris) phagocytosed [77, 78]. Uptake of 
diverse particles by specific receptors, suggests M1 
and M2 macrophages could use different internal 
mechanisms to process phagocytic particles and 
differences in phagosome maturation (ie. pH changes 
and pathway kinetics). Recent work has shown M2 
macrophages may have increased phagosome 
maturation [79], however; for the purpose of this 
work, we did not explore downstream processes but 
instead used a broad microtubule inhibitor 
(Cytochalasin D) to block actin polymerization 
dependent phagocytosis and macropinocytosis. 
Control studies using agarose beads showed complete 
inhibition of bead uptake in M2 macrophages 
following CytoD treatment indicating CytoD 
concentrations were sufficient to block phagocytosis. 
Some studies have shown inhibitors can affect other 
endocytic pathways and we cannot rule out inhibition 
of clatherin-mediated endocytosis in addition to 
phagocytosis. However, several papers have 
demonstrated that CytoD treatment in macrophages, 
completely inhibit phagocytosis, but does not affect 
other endocytic pathways [80-82]. These data in 
combination with our in vivo reduction of M2 
macrophages suggests αvβ3 targeted NP can deliver 
drug to M2 macrophages that avoids degradation in 
the phagocytic pathway, resulting in more efficacious 
concentrations of drug in the cytosol. 
A key finding of this work was the observation 
that integrin β3 is expressed on human breast cancer 
tumor-associated macrophages. In this paper we used 
tumor cell lines expressing β3 or β3 KO tumor cell 
lines to examine the effects of αvβ3-MI3-PD 
nanotherapy on β3-expressing macrophages. Because 
triple-negative breast cancers express elevated levels 
of MYC, we speculate that future studies developing 
similar tumor cell lines may help explore this dual 
targeting strategy in this group of patients, who have 
limited options for targeted therapies. 
Many other cell types in the tumor 
microenvironment express αvβ3 integrin including: 
tumor induced angiogenic cells, bone-residing 





osteoclasts, immune cells, and some types of tumor 
cells which could be targeted by the αvβ3-MI3-PD NP 
[83]. However, the integrin αvβ3-targeting 
peptidomimetic binds with high affinity to the ligand- 
binding domain exposed with activated integrins, 
avoiding binding to inactivated αvβ3 integrin on 
quiescent cells. We have previously shown that 
integrin αvβ3-targeting to the neovasculature can be 
used to specifically deliver cargoes with αvβ3-PFC NP 
in pathologic animal models of cardiovascular, 
inflammatory disease and cancer [54, 84, 85]. The 
cMYC-MAX pathway is upregulated in tumor 
neovasculature, which also expresses the activated 
integrin [86]. αvβ3-fumagillin NP target targeting 
neovascular endothelial induce apoptosis releasing 
nitric oxide that can suppress macrophage 
inflammatory responses [84]. Importantly, αvβ3 is 
only expressed on newly forming blood vessels and 
not the established tumor vasculature. Thus, the 
positive anti-tumor response observed with αvβ3- 
MI3-PD NP may reflect a complicated anti-tumor 
response. 
 Our data show that cMYC-MAX is an opportune 
therapeutic target for manipulating the TAM 
population away from tumor-promoting 
macrophages and that a small molecule antagonist, 
modified into a phosphatidylcholine prodrug, 
protected the compound from metabolism during 
circulation and allowed a unique αvβ3 NP delivery 
mechanism (CFDD) to circumvent enzymatic 
degradation within the phagocytosis pathway and 
discharge directly into the intracellular membranes. 
Future research will need to refine and optimize this 
concept with a focus on corroborative 
immunohistological analysis, longer treatment 
courses, treatment of larger tumors, and evaluation in 
metastatic models. Additionally, the further use of 
CRISPR/Cas9 to disrupt integrin β3 expression in 4T1 
breast cancer line could establish a useful breast 
cancer model to further evaluate whether αvβ3-MI3- 
PD NPs are effective against tumor cells in vivo, and 
the use of a smaller 20nm nanoparticle, similar to that 
we reported in multiple myeloma models [67], may 
enhance tumor penetration and effective 
extravasation. Finally, we propose to investigate 
whether macrophage repolarization using αvβ3-MI3- 
PD NPs can enhance responses to immune checkpoint 
inhibitors in breast cancer models. 
In summary, this research demonstrates the 
potential of MYC-MAX inhibition with a small 
molecule to affect specific changes in the tumor 
promoting M2 macrophage population. A free small 
molecule inhibitor known to have poor stability in 
circulation was modified into a lipid prodrug and 
incorporated into the phospholipid surfactant of 
targeted perfluorocarbon nanoparticles. MYC 
inhibition in vitro decreased markers of M2 
polarization while αvβ3-mediated drug delivery of 
the MYC inhibitor MI3-PD, decreased numbers of M2 
TAMs without decreasing M1 macrophages in mouse 
models of ER+ and triple-negative breast cancer. 
Moreover, BLI of these breast cancer models 
demonstrated significant reductions in tumor cells 
following αvβ3-MI3-PD NP treatment. The 
overarching conclusion of this research is that cMYC- 
MAX inhibition is an important mechanistic target for 
anti-tumor treatment, particularly regarding the TAM 
population relative polarization, which is enabled by 
αvβ3-targeted nanotherapy. 
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umbilical vein endothelial cells; IACUC: institutional 
animal care and use committee; IFN-λ: interferon 
gamma; IL-4: interleukin 4; KO: knockout; M-CSF: 
macrophage colony-stimulating factor; MDSC: 
myeloid derived suppressor cell; MEM Alpha: 
minimum essential medium; MFI: median 
fluorescence intensity; MFP: mammary fat pad; MI3: 
myc inhibitor 3 [2-Hydroxyethyl 4'-methyl-6-((7- 
nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)-[1,1'-biphe
nyl]-3-carboxylate]; MMTV-PyMT: mouse mammary 
tumor virus – polyomavirus middle T-antigen; MPS: 
macrophage monocyte phagocytic system; MTT: 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide; NP: nanoparticle; PBS: phosphate buffered 
saline; PD: prodrug; PFC: perfluorocarbon; RPM: 
revolutions per minute; SEM: standard error of the 
mean; TAM: tumor-associated macrophages; TuCM: 
tumor conditioned media; αvβ3: integrin heterodimer 
of subunits αv and β3; αvβ3-NP: αvβ3 targeted 
nanoparticles. 
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